George Vande Woude
Overview
Explore the profile of George Vande Woude including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
1280
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pal K, Bandyopadhyay A, Zhou X, Xu Q, Marciano D, Brunzelle J, et al.
Structure
. 2017 May;
25(6):867-877.e3.
PMID: 28528776
The nuclear pore complex subunit TPR is found in at least five different oncogenic fusion kinases, including TPR-MET, yet how TPR fusions promote activation of kinases and their oncogenic activities...
2.
Huang F, Ma Z, Pollan S, Yuan X, Swartwood S, Gertych A, et al.
J Pathol Clin Res
. 2016 Oct;
2(4):210-222.
PMID: 27785366
The limited clinical success of anti-HGF/MET drugs can be attributed to the lack of predictive biomarkers that adequately select patients for treatment. We demonstrate here that quantitative digital imaging of...
3.
Dykes S, Gao C, Songock W, Bigelow R, Vande Woude G, Bodily J, et al.
Mol Carcinog
. 2016 Jul;
56(2):722-734.
PMID: 27434882
Tumor cell invasion through the extracellular matrix is facilitated by the secretion of lysosome-associated proteases. As a common mechanism for secretion, lysosomes must first traffic to the cell periphery (anterograde...
4.
Nickoloff B, Vande Woude G
Pigment Cell Melanoma Res
. 2012 Sep;
25(6):758-61.
PMID: 22974232
No abstract available.
5.
Kentsis A, Reed C, Rice K, Sanda T, Rodig S, Tholouli E, et al.
Nat Med
. 2012 Jun;
18(7):1118-22.
PMID: 22683780
Although the treatment of acute myeloid leukemia (AML) has improved substantially in the past three decades, more than half of all patients develop disease that is refractory to intensive chemotherapy....
6.
Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G
Nat Rev Cancer
. 2012 Jan;
12(2):89-103.
PMID: 22270953
Uncontrolled cell survival, growth, angiogenesis and metastasis are essential hallmarks of cancer. Genetic and biochemical data have demonstrated that the growth and motility factor hepatocyte growth factor/scatter factor (HGF/SF) and...
7.
Scott K, Nogueira C, Heffernan T, van Doorn R, Dhakal S, Hanna J, et al.
Cancer Cell
. 2011 Jul;
20(1):92-103.
PMID: 21741599
Clinical and genomic evidence suggests that the metastatic potential of a primary tumor may be dictated by prometastatic events that have additional oncogenic capability. To test this "deterministic" hypothesis, we...
8.
Tolbert W, Daugherty-Holtrop J, Gherardi E, Vande Woude G, Xu H
Proc Natl Acad Sci U S A
. 2010 Jul;
107(30):13264-9.
PMID: 20624990
Hepatocyte growth factor (HGF) is an activating ligand of the Met receptor tyrosine kinase, whose activity is essential for normal tissue development and organ regeneration but abnormal activation of Met...
9.
Paneth N, Vande Woude G, Kort E
JAMA
. 2010 Mar;
303(11):1032-3.
PMID: 20233816
No abstract available.
10.
Knudsen B, Zhao P, Resau J, Cottingham S, Gherardi E, Xu E, et al.
Appl Immunohistochem Mol Morphol
. 2008 Sep;
17(1):57-67.
PMID: 18815565
The inappropriate expression of the c-MET cell surface receptor in many human solid tumors necessitates the development of companion diagnostics to identify those patients who could benefit from c-MET targeted...